Last reviewed · How we verify
L1-79
At a glance
| Generic name | L1-79 |
|---|---|
| Also known as | DL-alpha-Methyltyrosine, D,L-α-Methyltyrosine |
| Sponsor | Yamo Pharmaceuticals LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety of L1-79 in Adolescent and Adult Males With Autism (PHASE2)
- A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L1-79 CI brief — competitive landscape report
- L1-79 updates RSS · CI watch RSS
- Yamo Pharmaceuticals LLC portfolio CI